Article Data

  • Views 2654
  • Dowloads 243

Brief Reports

Open Access

The vaccination against COVID-19 in Morocco: a success story in progress

  • Rachid Ait Addi1
  • Abdelhafid Benksim1,2
  • Mohamed Cherkaoui1

1Laboratory of Human Ecology, Department of Biology, School of Sciences Semlalia, Cadi Ayyad University, 40080 Marrakech, Morocco

2High Institute of Nursing and Technical Health, 42074 Marrakech, Morocco

DOI: 10.22514/sv.2021.080 Vol.17,Issue 3,May 2021 pp.250-255

Submitted: 06 April 2021 Accepted: 16 April 2021

Published: 08 May 2021

*Corresponding Author(s): Rachid Ait Addi E-mail:


Coronavirus disease 2019 is a respiratory sickness that may spread between persons. It is caused by a novel coronavirus that produces an outbreak in Wuhan, China and spread all over the world to become a pandemic. From the appearance of the first case of the new coronavirus in Morocco, Moroccan authorities has spared no effort to promote the health of Moroccans, ahead of that of the country’s economy. On 22 January 2021, 2 million doses, of AstraZeneca COVID-19 vaccine were delivered to Morocco, with a view to vaccinating 1 million Moroccans in a first phase. On 28 January, the campaign started and the King of Morocco was the 1st Moroccan to be vaccinated against the coronavirus. On 27 February 2021, Morocco has received 1 million doses from the Chinese laboratory Sinopharm and 6 million doses of the AstraZeneca vaccine allowing Morocco to vaccinate several audiences and the general public over the age of 60, and the most vulnerable. Thereafter, the COVID-19 vaccine doses administered per 100 people in 31 March 2021 were 115.89 in Israel, 84.01 in the United Arab Emirates, 52.53 in the United Kingdom, 44.93 in the United States, 45.04 in Bahrain, 21.66 in Morocco, 16.44 in Germany, 8.32 in China, 4.72 in India, and 0.44 in South Africa. Also, the population fully vaccinated against COVID-19 in 01 April 2021 were 55.51% in Israel, 22.12% in the United Arab Emirates, 20.08% in Chile, 16.77% in USA, 15.25% in Serbia, 15.14% in Bahrain, 10.21% in Morocco, 8.94% in Hungary, 8.23% in Turkey, 7.29% in UK, 3.07% in Russia, 2.39% in Brazil, 1.70% in Uruguay, 0.70% in India, and 0.45% in South Africa. This allows Morocco to figure in the top 10 countries fully vaccinated against COVID-19 despite the lack of resources and belonging to developing countries. Finally, our study gives an example to other countries to benefit from the Moroccan experience. Nevertheless, vaccination is only one element of a comprehensive COVID-19 strategy, it must be accompanied by measures to reduce circulating infection and keep them low.


COVID-19; Morocco; Vaccination; Pandemic

Cite and Share

Rachid Ait Addi,Abdelhafid Benksim,Mohamed Cherkaoui. The vaccination against COVID-19 in Morocco: a success story in progress. Signa Vitae. 2021. 17(3);250-255.


[1] World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https: // (Accessed: 27 April 2021).

[2] Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020; 368: 489–493.

[3] Ait Addi R, Benksim A, Amine M, Cherkaoui M. COVID-19 outbreak and perspective in Morocco. Electronic Journal of General Medicine. 2020; 17: em204.

[4] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020; 382: 1708–1720.

[5] Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. Journal of Internal Medicine. 2020; 288: 335–344.

[6] Bai Y, Yao L, Wei T, Tian F, Jin D, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. Journal of the American Medical Association. 2020; 323: 1406–1407.

[7] Ali I, Alharbi OML. COVID-19: disease, management, treatment, and social impact. Science of the Total Environment. 2020; 728: 138861.

[8] Our World in Data. Coronavirus Pandemic (COVID-19)—the data. 2021. Available at : (Accessed: 02 April 2021).

[9] Le Point. Vaccins anti-COVId-19: le Maroc prend le taureau par les cornes. 2021. Available at: (Accessed: 02 April 2021).

[10] Premkumar M, Sundararajan TVP. DLDM: deep learning-based defense mechanism for denial of service attacks in wireless sensor networks. Microprocessors and Microsystems. 2020; 79: 103278.

[11] Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021; 21: 181–192.

[12] Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. Double-Blind, Randomized, Placebo-Controlled Phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac—PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21: 853.

[13] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396: 467–478.

[14] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397: 99–111.

[15] Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396: 1979–1993.

[16] Moroccan Minisrty of Health. COVID-19: Le ministère de la Santé pour le maintien du vaccin Sinopharm chez les 60 ans et plus. 2021. Available at: source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiznNm-4-LvAhWxSxUIHW12DUMQFjAJegQIChAD&url=https%3A%2F%2Fwww. (Accessed: 02 April 2021).

[17] Le Desk. Covax/Vaccin anti-covid: Le Maroc recevera 1,88 millions de doses. 2021. Available at: (Accessed: 02 April 2021).

[18] CDC. Pfizer-BioNTech COVID-19 Vaccine. 2021. Available at: (Accessed: 02 April 2021).

[19] Ministre de la Santé. Le Maroc acquiert le premier lot du vaccin contre le virus de la Covid-19. 2021. Available at: https://www.sante. (Accessed: 02 April 2021).

[20] INFO. Coronavirus: le Maroc lance une campagne de vaccination ambitieuse. 2021. Available at: https://information.tv5monde. com/video/coronavirus-le-maroc-lance-une-campagne-de-vaccination-ambitieuse (Accessed: 02 April 2021).

[21] Jomni M. Covid-19/Maroc: Arrivée du deuxième lot du vaccin britannique “AstraZeneca”. 2021. Available at: tr/fr/afrique/covid-19-maroc-arriv%C3%A9e-du-deuxi%C3%A8me-lot-du-vaccin-britannique-astrazeneca/2142006 (Accessed: 02 April 2021).

[22] INFO. Covid-19: le Maroc en marche vers la vaccination. 2021. Available at:

le-maroc-lance-une-campagne-de-vaccination-ambitieuse (Accessed: 03 April 2021).

[23] Our World in Data. Coronavirus (COVID-19) Vaccinations - Statistics

and Research - Our World in Data. (Accessed: 27 April 2021)

[24] WeLT. Wie auch der Impf-Champion in Nordafrika Deutschland abhängt. 2021. Available at: https://www. Marokko-Impf-Champion-inNordafrika.html fbclid= IwAR2AyY84zhlQNEHi6aQlEIrUQaoO64Ttr682Lbo4XXwgBXSUPx4fCQY3D8I (Accessed: 03 April 2021).

[25] MEDIAS. Phase 3 des essais cliniques Sinopharm: La sérologie

des 6 mois bientôt effectuée. 2021. Available at: https://www.

la-serologie-des-6-mois-bientot-effectuee-16706.html (Accessed: 03 April 2021).

[26] McKee M, Rajan S. What can we learn from Israel’s rapid roll out of COVID 19 vaccination? Israel Journal of Health Policy Research. 2021; 10: 5.

[27] Our World in Data. Coronavirus (COVID-19) vaccinations. Available at: (Accessed: 03 April 2021).

[28] Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Israel Journal of Health Policy Research. 2021; 10: 6.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time